DeepMed Research

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

Phase 1

Completed

Conditions: Vitrectomy

Interventions: Drug: 400 µg Brimonidine Tartrate Implant
Drug: 200 µg Brimonidine Tartrate Implant

First Posted Date: 2010-10-27

Last Posted Date: 2013-08-05

Lead Sponsor: Allergan

Target Recruit Count: 24

Registration Number: NCT01229410

Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Not Applicable

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: brimonidine tartrate/timolol fixed combination ophthalmic solution
Drug: brimonidine tartrate ophthalmic solution
Other: fixed combination vehicle
Drug: timolol ophthalmic solution

First Posted Date: 2010-10-27

Last Posted Date: 2012-09-14

Lead Sponsor: Allergan

Target Recruit Count: 238

Registration Number: NCT01229462

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Phase 3

Completed

Conditions: Facial Rhytides
Glabellar Lines
Crow's Feet Lines

Interventions: Drug: normal saline
Biological: onabotulinumtoxinA 44 U
Biological: onabotulinumtoxinA 24 U

First Posted Date: 2010-10-19

Last Posted Date: 2014-02-25

Lead Sponsor: Allergan

Target Recruit Count: 684

Registration Number: NCT01224015

Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
Drug: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)

First Posted Date: 2010-10-08

Last Posted Date: 2016-12-20

Lead Sponsor: Allergan

Target Recruit Count: 185

Registration Number: NCT01217606

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Phase 1

Completed

Conditions: Ocular Hypertension
Glaucoma, Open-Angle

Interventions: Drug: AGN-207281 vehicle ophthalmic solution (Placebo)
Drug: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)
Drug: timolol ophthalmic solution 0.5%

First Posted Date: 2010-10-07

Last Posted Date: 2015-08-17

Lead Sponsor: Allergan

Target Recruit Count: 50

Registration Number: NCT01215786

Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Ocular Hypertension
Glaucoma

Interventions: Drug: bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution

First Posted Date: 2010-10-07

Last Posted Date: 2013-09-19

Lead Sponsor: Allergan

Target Recruit Count: 126

Registration Number: NCT01216943

Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: MAP0004
Drug: IV DHE

First Posted Date: 2010-09-13

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 47

Registration Number: NCT01199965

Locations: 🇬🇧
Simbec Research Limited, Merthyr Tydfil, United Kingdom

Safety and Effectiveness of Juvederm(R) Ultra XC Injectable Gel for Lip Augmentation

Not Applicable

Completed

Conditions: Lip Augmentation

Interventions: Device: hyaluronic acid gel

First Posted Date: 2010-09-09

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 213

Registration Number: NCT01197495

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MAP0004
Drug: Inhaler Placebo
Drug: Moxifloxacin
Drug: Placebo Capsule

First Posted Date: 2010-08-31

Last Posted Date: 2014-01-09

Lead Sponsor: Allergan

Target Recruit Count: 54

Registration Number: NCT01191723

Locations: 🇺🇸
Cetero Research, Fargo, North Dakota, United States

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

Phase 3

Completed

Conditions: Crow's Feet Lines
Lateral Canthus Rhytides

Interventions: Drug: normal saline
Biological: onabotulinumtoxinA

First Posted Date: 2010-08-27

Last Posted Date: 2019-05-07

Lead Sponsor: Allergan

Target Recruit Count: 446

Registration Number: NCT01189747

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy